{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:12:25Z","timestamp":1791583945461,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/leu.2008.221","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T09:48:50Z","timestamp":1219916930000},"page":"2176-2183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase"],"prefix":"10.1038","volume":"22","author":[{"given":"J","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D-W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Corm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-L","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T H","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rege-Cambrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M A","family":"Van Tornout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"BFleu2008221_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0002-9343(93)90122-6","volume":"94","author":"PM Derderian","year":"1993","unstructured":"Derderian PM, Kantarjian HM, Talpaz M, O\u2019Brien S, Cork A, Estey E et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993; 94: 69\u201374.","journal-title":"Am J Med"},{"key":"BFleu2008221_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321\u20131331.","journal-title":"Leukemia"},{"key":"BFleu2008221_CR3","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S, Kantarjian HM, O\u2019Brien S, Cortes J, Rios MB, Giles FJ et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632\u20132641.","journal-title":"Cancer"},{"key":"BFleu2008221_CR4","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1182\/blood.V99.7.2304","volume":"99","author":"J Wadhwa","year":"2002","unstructured":"Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99: 2304\u20132309.","journal-title":"Blood"},{"key":"BFleu2008221_CR5","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530\u20133539.","journal-title":"Blood"},{"key":"BFleu2008221_CR6","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965\u20131971.","journal-title":"Blood"},{"key":"BFleu2008221_CR7","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"S Soverini","year":"2005","unstructured":"Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100\u20134109.","journal-title":"J Clin Oncol"},{"key":"BFleu2008221_CR8","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658\u20136661.","journal-title":"J Med Chem"},{"key":"BFleu2008221_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu2008221_CR10","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207\u20133213.","journal-title":"Blood"},{"key":"BFleu2008221_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"C Clopper","year":"1934","unstructured":"Clopper C, Pearson E . The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404\u2013413.","journal-title":"Biometrika"},{"key":"BFleu2008221_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200\u20131206.","journal-title":"Leukemia"},{"key":"BFleu2008221_CR13","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinin-resistant or -intolerant chronic myeloid leukemia. Blood 2007; 109: 4143\u20134150.","journal-title":"Blood"},{"key":"BFleu2008221_CR14","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500\u20134505.","journal-title":"Cancer Res"},{"key":"BFleu2008221_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFleu2008221_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","volume":"2007","author":"JP Radich","year":"2007","unstructured":"Radich JP . The biology of CML blast crisis. Hematology (Am Soc Hematol Educ Program) 2007; 2007: 384\u2013391.","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"BFleu2008221_CR17","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1038\/sj.onc.1206008","volume":"21","author":"MB Wilson","year":"2002","unstructured":"Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE . Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21: 8075\u20138088.","journal-title":"Oncogene"},{"key":"BFleu2008221_CR18","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766\u20135774.","journal-title":"EMBO J"},{"key":"BFleu2008221_CR19","doi-asserted-by":"publisher","first-page":"18581","DOI":"10.1074\/jbc.C000126200","volume":"275","author":"JM Lionberger","year":"2000","unstructured":"Lionberger JM, Wilson MB, Smithgall TE . Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581\u201318585.","journal-title":"J Biol Chem"},{"key":"BFleu2008221_CR20","doi-asserted-by":"publisher","first-page":"30907","DOI":"10.1074\/jbc.M605902200","volume":"281","author":"MA Meyn III","year":"2006","unstructured":"Meyn III MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907\u201330916.","journal-title":"J Biol Chem"},{"key":"BFleu2008221_CR21","doi-asserted-by":"publisher","first-page":"16870","DOI":"10.1073\/pnas.0606509103","volume":"103","author":"Y Hu","year":"2006","unstructured":"Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S . Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870\u201316875.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2008221_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFleu2008221_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm1127","volume":"10","author":"A Ptasznik","year":"2004","unstructured":"Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187\u20131189.","journal-title":"Nat Med"},{"key":"BFleu2008221_CR24","doi-asserted-by":"publisher","first-page":"34227","DOI":"10.1074\/jbc.M402290200","volume":"279","author":"Y Dai","year":"2004","unstructured":"Dai Y, Rahmani M, Corey SJ, Dent P, Grant S . A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227\u201334239.","journal-title":"J Biol Chem"},{"key":"BFleu2008221_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1600-0609.2007.00835.x","volume":"78","author":"T Ito","year":"2007","unstructured":"Ito T, Tanaka H, Kimura A . Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 2007; 78: 417\u2013431.","journal-title":"Eur J Haematol"},{"key":"BFleu2008221_CR26","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908\u20133914.","journal-title":"J Clin Oncol"},{"key":"BFleu2008221_CR27","doi-asserted-by":"publisher","first-page":"11410","DOI":"10.1073\/pnas.96.20.11410","volume":"96","author":"R Heuchel","year":"1999","unstructured":"Heuchel R, Berg A, Tallquist M, Ahlen K, Reed RK, Rubin K et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3\u2032 kinase signaling. Proc Natl Acad Sci USA 1999; 96: 11410\u201311415.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2008221_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141: 745\u2013747.","journal-title":"Br J Haematol"},{"key":"BFleu2008221_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cncr.11863","volume":"100","author":"TB Sneed","year":"2004","unstructured":"Sneed TB, Kantarjian HM, Talpaz M, O\u2019Brien S, Rios MB, Bekele BN et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100: 116\u2013121.","journal-title":"Cancer"},{"key":"BFleu2008221_CR30","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2008221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008221","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2008221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:15:41Z","timestamp":1648725341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2008221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["BFleu2008221"],"URL":"https:\/\/doi.org\/10.1038\/leu.2008.221","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]},"assertion":[{"value":"16 May 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}